Home > Insider Trading > Filing (0001493152-20-003252)

Filing Details

Accession Number:: 0001493152-20-003252
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-03-03 11:09:56
Reporting Period:: 2020-02-28

Accepted Time:: 2020-03-03 11:09:56
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1651944	Dermtech Inc.	DMTK	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1493215	Rtw Investments, Lp	412 West 15Th Street, Floor 9 New York NY 10011		No	No	Yes	No
1493280	Roderick Wong	C/O Rtw Investments, Lp 412 West 15Th Street, Floor 9 New York NY 10011		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-02-28	152,456	$10.50	2,539,327	No	4	P	Indirect	By RTW
Common Stock	Acquisiton	2020-03-02	15,000	$12.83	2,554,327	No	4	P	Indirect	By RTW

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By RTW
No	4	P	Indirect	By RTW

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B-1 Preferred shares	Acquisiton	2020-02-28	228	$10,500.00	228,496	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
228			No	4	P	Indirect

Footnotes

On February 28, 2020 the Issuer entered into a definitive securities purchase agreement with certain institutional investors (the "Private Placement"). The Private Placement consists of 2,467,724 shares of common stock at a price of $10.50 per share and approximately 3,199 and 524 shares of Series B-1 Convertible Preferred Stock and Series B-2 Convertible Preferred Stock, respectively, each at a price of $10,500.00 per share. Each share of Series B-1 Convertible Preferred Stock will automatically convert into 1,000 shares of the Issuer's common stock upon the approval of the Private Placement by the stockholders of the Issuer, which the Issuer has agreed to seek at a meeting to be held on or before June 30, 2020 ("Stockholder Approval"). The 152,456 shares of common stock and 228.4963 Series B-1 Preferred shares reported herein were acquired pursuant to the Private Placement.
The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP ("RTW"), which is deemed the beneficial owner of shares held by RTW Master Fund, Ltd., RTW Venture Fund Limited and RTW Innovation Master Fund, Ltd. (the "Funds"), which are investment funds managed by RTW, and (ii) Roderick Wong, M.D who serves as the Managing Partner and Chief Investment Officer of RTW. Dr. Wong exercises voting and dispositive control over the securities held by RTW and is therefore deemed to be a beneficial owner of securities owned or controlled by RTW. Each of RTW and Dr. Wong disclaim beneficial ownership of the reported securities held by the Funds, except to the extent of its or his pecuniary interest therein.